FierceBiotech ٩ مارس ٢٠٢٦ Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China
FierceBiotech ٩ مارس ٢٠٢٦ Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
FierceBiotech ٩ مارس ٢٠٢٦ Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
FierceBiotech ٩ مارس ٢٠٢٦ Why early developability assessment is a strategic necessity in modern antibody discovery
FierceBiotech ٦ مارس ٢٠٢٦ FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
FierceBiotech ٦ مارس ٢٠٢٦ Beam rejigs deal to retain base editing technology amid partner's dissolution
FierceBiotech ٦ مارس ٢٠٢٦ Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda
FierceBiotech ٦ مارس ٢٠٢٦ Senior FDA official refutes uniQure's claims amid controversy over Huntington's gene therapy
FierceBiotech ٦ مارس ٢٠٢٦ Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
FierceBiotech ٦ مارس ٢٠٢٦ Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug